Insider · CIK 0001559827
Anthony A. Florence Jr.
Files at SYBX (SYNLOGIC, INC.), NEUE (NeueHealth, Inc.), KRRO (Korro Bio, Inc.), SGP (SpyGlass Pharma, Inc.). First filing Oct 6, 2025, latest Mar 12, 2026.
In brief
Anthony A. Florence Jr. files SEC Form 4 as 10% owner and director at NEUE (NeueHealth, Inc.), and also at KRRO (Korro Bio, Inc.), SGP (SpyGlass Pharma, Inc.), SYBX (SYNLOGIC, INC.). Since Oct 6, 2025, Anthony A. Florence Jr. has reported 2 open-market buys worth $17M and 1 open-market sell worth $28k, the latest filed on Mar 12, 2026.
A track record needs three past buys with six months of prices behind them; Anthony A. Florence Jr. has 0, so none is measured yet.
The newest scored trade: bought $2.3M of KRRO on Mar 10, 2026, filed Mar 12, 2026, scored 58 (moderate). In the last 12 months: 2 buys worth $17M and 0 sells worth $0.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
KRRO: Korro Bio, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
SGP: SpyGlass Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | Korro Bio, Inc. | $2.3M 207,100 shares | +19% | +117% from low-78% from high | |
| 50Moderate | SpyGlass Pharma, Inc. | $15M 937,500 shares | +18% | - | |
| 20Weak | NeueHealth, Inc. | $28k 4,195 shares | -0% | - |
Transactions
The newest 50 of 55 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | KRRO Korro Bio, Inc. | POpen-market purchase Common Stockindirect: See Note 2 | +207,100 | $11.11 | $2.3M | 1,297,893 | Mar 12, 2026 |
| Mar 10, 2026 | KRRO Korro Bio, Inc. | POpen-market purchase Pre-Funded Warrantsderivativeindirect: See Note 2 | +242,945 | $11.11 | $2.7M | 242,945 | Mar 12, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See Note 2 | +1,619,240 | - | - | 1,619,240 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See Note 2 | +1,370,168 | - | - | 2,989,408 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See Note 2 | +1,370,168 | - | - | 4,359,576 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See Note 2 | +737,962 | - | - | 5,097,538 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | POpen-market purchase Common Stockindirect: See Note 2 | +937,500 | $16.00 | $15M | 6,035,038 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See Note 3 | +954,990 | - | - | 954,990 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See Note 3 | +402,273 | - | - | 1,357,263 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series B Preferred Stockderivativeindirect: See Note 2 | -1,619,240 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: See Note 2 | -1,370,168 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series C-2 Preferred Stockderivativeindirect: See Note 2 | -1,370,168 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series D Preferred Stockderivativeindirect: See Note 2 | -737,962 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series A Preferred Stockderivativeindirect: See Note 3 | -954,990 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series B Preferred Stockderivativeindirect: See Note 3 | -402,273 | - | - | 0 | Feb 11, 2026 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | XIn-the-money exercise Common Stockindirect: See Note 1 | +189,195 | $0.01 | $1,892 | 1,527,217 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | SOpen-market sale Common Stockindirect: See Note 1 | -280 | $6.75 | $1,890 | 1,526,937 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | MOption exercise Common Stockindirect: See Note 1 | +434,297 | $0.01 | $4,343 | 1,961,234 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | FTax withholding Common Stockindirect: See Note 1 | -643 | $6.75 | $4,340 | 1,960,591 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | DDisposition to issuer Common Stockindirect: See Note 1 | -1,960,591 | - | - | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | DDisposition to issuer Common Stockindirect: See Note 4 | -43,678 | - | - | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | XIn-the-money exercise Common Stockindirect: See Note 5 | +189,195 | $0.01 | $1,892 | 788,259 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | SOpen-market sale Common Stockindirect: See Note 5 | -280 | $6.75 | $1,890 | 787,979 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | MOption exercise Common Stockindirect: See Note 5 | +372,255 | $0.01 | $3,723 | 1,160,234 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | FTax withholding Common Stockindirect: See Note 5 | -551 | $6.75 | $3,719 | 1,159,683 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | DDisposition to issuer Common Stockindirect: See Note 5 | -1,159,683 | - | - | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | XIn-the-money exercise Common Stockindirect: See Note 6 | +189,195 | $0.01 | $1,892 | 488,982 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | SOpen-market sale Common Stockindirect: See Note 6 | -280 | $6.75 | $1,890 | 488,702 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | MOption exercise Common Stockindirect: See Note 6 | +186,128 | $0.01 | $1,861 | 674,830 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | FTax withholding Common Stockindirect: See Note 6 | -276 | $6.75 | $1,863 | 674,554 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | DDisposition to issuer Common Stockindirect: See Note 6 | -674,554 | - | - | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | XIn-the-money exercise Common Stockindirect: See Note 7 | +1,656,789 | $0.01 | $17k | 1,656,789 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | SOpen-market sale Common Stockindirect: See Note 7 | -2,455 | $6.75 | $17k | 1,654,334 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | XIn-the-money exercise Common Stockindirect: See Note 7 | +607,536 | $0.01 | $6,075 | 2,261,870 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | SOpen-market sale Common Stockindirect: See Note 7 | -900 | $6.75 | $6,075 | 2,260,970 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | MOption exercise Common Stockindirect: See Note 7 | +124,085 | $0.01 | $1,241 | 2,385,055 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | FTax withholding Common Stockindirect: See Note 7 | -182 | $6.75 | $1,229 | 2,384,873 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | DDisposition to issuer Common Stockindirect: See Note 7 | -2,384,873 | - | - | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | XIn-the-money exercise Warrant (Right to Buy)derivativeindirect: See Note 1 | -189,195 | $0.00 | $0 | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | AGrant or award Warrant (Right to Buy)derivativeindirect: See Note 1 | +434,297 | - | - | 434,297 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | MOption exercise Warrant (Right to Buy)derivativeindirect: See Note 1 | -434,297 | $0.00 | $0 | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | XIn-the-money exercise Warrant (Right to Buy)derivativeindirect: See Note 5 | -189,195 | $0.00 | $0 | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | AGrant or award Warrant (Right to Buy)derivativeindirect: See Note 5 | +372,255 | - | - | 372,255 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | MOption exercise Warrant (Right to Buy)derivativeindirect: See Note 5 | -372,255 | $0.00 | $0 | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | XIn-the-money exercise Warrant (Right to Buy)derivativeindirect: See Note 6 | -189,195 | $0.00 | $0 | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | AGrant or award Warrant (Right to Buy)derivativeindirect: See Note 6 | +186,128 | - | - | 186,128 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | MOption exercise Warrant (Right to Buy)derivativeindirect: See Note 6 | -186,128 | $0.00 | $0 | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | DDisposition to issuer Series A Convertible Perpetual Preferred Stockderivativeindirect: See Note 6 | -75,000 | - | - | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | DDisposition to issuer Series B Convertible Perpetual Preferred Stockderivativeindirect: See Note 6 | -37,700 | - | - | 0 | Oct 6, 2025 |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | XIn-the-money exercise Warrant (Right to Buy)derivativeindirect: See Note 7 | -1,656,789 | $0.00 | $0 | 0 | Oct 6, 2025 |
Questions about Anthony A. Florence Jr.
Answered from the filings on this page, as of the latest one.
Is Anthony A. Florence Jr. buying or selling?
In the last 12 months Anthony A. Florence Jr. reported 2 open-market buys worth $17M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $2.3M of KRRO on Mar 10, 2026. Grants, option exercises and tax withholding are not counted.
How did Anthony A. Florence Jr.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Anthony A. Florence Jr. has 0.
Where does Anthony A. Florence Jr. file Form 4?
Anthony A. Florence Jr. has filed Form 4 at NEUE (NeueHealth, Inc.); KRRO (Korro Bio, Inc.); SGP (SpyGlass Pharma, Inc.); SYBX (SYNLOGIC, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.